Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Ovarian Cancer treatment details. Chemotherapy. MD Anderson Cancer Center, University of Texas, Houston, TX, United States



Survival: 14.0 months
   
Toxicity Grade: 4
   
Treatments: Chemotherapy
   
Drugs:
Country: United States
   
City/State/Province: Houston, TX
   
Hospital: MD Anderson Cancer Center, University of Texas
   
Journal: Link
   
Date: 11/2010

Description:
Patients:
This study involved 30 women with epithelial ovarian cancer whose cancer had progressed following prior platinum-based chemotherapy. The median patient age was 63 years.

Treatment:
Patients were treated with a combination of two chemotherapy agents, azacitidine and carboplatin.

Toxicities:
The maximum toxicity level reported was grade 4, including neutropenia and thrombocytopenia. Also, 30% of patients experienced grade 3 fatigue and 13.3% reported grade 3 pain at injection site.

Results:
The median progression-free survival for this study was 3.7 months. The median overall survival was 14 months.

Support:
This study was supported by Pharmion Corp., makers of azacitidine (trade name: Vidaza).

Correspondence: Dr. Siqing Fu; email: siqingfu@mdanderson.org

E-mail to a Friend Email Physician More Information